Your donation will make a difference:
Cystic Fibrosis Trust

Trials Tracker

Welcome to the Trials Tracker, bringing together all the cystic fibrosis (CF) trials currently recruiting in the UK so that you can find clinical trials you can take part in both in your region and further afield. The Trials Tracker is a new resource that we’ll be developing over time based on your feedback. If you’ve used the Trials Tracker and want to share your opinion, please complete our online poll or get in touch at clinicaltrials@cysticfibrosis.org.uk.

Please Log in

Log in

Not a registered user? Register with us

This trial will be added to your watchlist.

Do you want to receive email notifications when the trial status changes?

No Yes

Unfollowing a trial will remove it from the watchlist and stop status change email notifications

Are you sure you want to unfollow this trial?

Yes, remove from watchlist

Clinical trials

1-5 of 30 results for all trials

Sort by:

Filter by

Trial status

Inclusion age

FEV1

Study design

Location

Mutation

Therapeutic category

Gut - CF

Cystic fibrosis affects the digestive system and leads to a number of unpleasant symptoms. Those relating to the bowels are often overlooked and can be hard to treat. We are hoping to evaluate a new questionnaire –the CF bowel score (CF-BS)–specifically designed to look at CF bowel disease. We hope it will improve identification and allow us to measure response to treatment. The patient will complete the CF-BS at their routine clinic appointment along with providing relevant clinical information. One group of patients will be sent home with the CF-BS to complete at home and return to us within a week. A final group of patients will be asked to complete the form before and after certain treatments so we can assess how bowel symptoms change over a course of treatment. Once we are happy that the CF-BS questionnaire captures symptoms that affect CF patients it will be distributed to the rest of the patients at the Manchester Adult CF Centre. This will allow us to identify the number of patients with bowel symptoms and allow us to better treat them

  • Age

    18+

  • Length of participation

    1 week

  • Trial status

    Project in Setup

  • Therapeutic category

    Other

Gastro-oesphageal reflux in patients with cystic fibrosis and its effect on lung function

Gastro - oesophageal reflux disease(GORD) is a condition where acid from the stomach leaks out of the stomach and up into the oesophagus (gullet) It is common in patient with Cystic Fibrosis. Although symptoms such as heartburn and acid taste in the mouth can occur, often there are no symptoms. Studies have suggested a link between a worsening lung function and the amount of GORD. A potential mechanism is by the stomach content travelling into the lungs causing inflammation and altering the usual organisms that are present. If that is the case, there may be opportunities for new drugs and /or surgical procedures. The aim of this observational study is to investigate if GORD affects the lung function. The study will assess mircobiology and presence of markers of reflux aspiration. These are substances that are found in the gastrointrestinal tract and that , if detected in sputum, support the presence of stomach contents in the lungs. In addition factors that may influence GORD such as antacids tablets and enteral feeding ( via a tube into the stomach) will be evaluated. GORD will be measured by using special probes that assess the function of the oesophagus, PH (acidity) and presence of gastic contents within the gullet. The participants will provide measures of lung function, clinical details, blood, and sputum samples as well as complete symptoms questionnaires

  • Age

    18+

  • Length of participation

    24 hours

  • Trial status

    Open to recruitment

  • Therapeutic category

    Other

A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have a CFTR Gating Mutation

The purpose of this study is to evaluate the safety of ivacaftor treatment, and PK of ivacaftor and metabolites in subjects with cystic fibrosis (CF) who are <24 months of age at treatment initiation and have a CF transmembrane conductance regulator (CFTR) gene gating mutation

Phase III
  • Length of participation

    104 weeks

  • Trial status

    Open to recruitment

  • Therapeutic category

    Restore CFTR Function

VX14-661-110 Cystic Fibrosis

This is a Phase 3, OpenLabel, Rollover study to look at how safe and effective longterm treatment with VX-661 together with Ivacaftor is in paticipants aged 12 years and older with cystic fibrosis (CF) that have a F508de-lCFTR mutation. The study involves treating all participants who meet all the rules of the study from one of the parent studies (VX-661-106,108,109 or 111) with a combination of VX-661 and Ivacaftor for approximately 96 weeks with a follow-up 28 days after the last dose. Approximately 1375 participants are potentially eligible to be enrolled. There is also an observational cohort (group) that will enable participants under 18 years of age that received at least 4 weeks of the study drug in the parent study who meet the other rules of the study to enroll. These participants will not receive any study drug but they will have regularly scheduled telephone calls to assess post treatment safety of the combination of VX661/Ivacaftor.

Phase III
  • Length of participation

    96 weeks

  • Trial status

    Open

  • Therapeutic category

    Restore CFTR Function

Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis on KALYDECO® as Background Therapy

The single treatment group will enroll adult subjects with CF currently on stable KALYDECO® background therapy for a minimum of 3 months at the time of randomization. Subjects will be randomized to either PTI-428 or placebo. Each dose will be administered once daily (QD) for a total of 14 Days. The subjects will continue treatment with KALYDECO® throughout the study.

Phase I
  • Age

    18+

  • Length of participation

    21 weeks

  • Trial status

    Open to recruitment

  • Therapeutic category

    Restore CFTR Function

1-5 of 30 results for all trials